Table 1. Clinical and Demographics summary.
Results are given as mean (and standard deviation) unless otherwise stated. PSP refers to patients with PSP-Richardson’s syndrome. CBD refers to amyloid negative corticbasal syndrome. The F-statistic and p-values are derived from ANOVA. ACE-R: revised Addenbrooke’s Cognitive Examination, MMSE: Mini-mental State Examination, PSPRS: Progressive Supranuclear Palsy Rating Scale, CBFS: Cortical Basal ganglia Functional Scale, INECO: Institute of Cognitive Neurology frontal screening tool. a chi-squared test. ns = non-significant at p<0.05.
| Control | PSP | cbd | F (p) | |
|---|---|---|---|---|
| Gender (M:F) | 11:8 | 10:13 | 7:5 | nsa |
| Age at [11C]UCB-J PET in years | 68.9 (7.1) | 71.3 (8.6) | 70.9 (7.9) | ns |
| Symptom duration (years) | - | 3.9 (2.2) | 3.9 (2.1) | ns |
| Education (years) | 13.6 (2.8) | 12 (4.2) | 12.6 (2.8) | ns |
| ACE-R total (max. 100) | 96.7 (2.7) | 80.9 (12.4) | 77.5 (17.1) | 10.1 (<0.001) |
| Attention Orientation (max .18) | 17.9 (0.3) | 16.3 (1.9) | 16.3 (2.3) | 4.5 (0.02) |
| Memory (max .26) | 24.6 (1.7) | 21.8 (3.8) | 20.9 (5.3) | 5.3 (0.01)) |
| Fluency (max . 14) | 12.8 (1.0) | 6.6 (3) | 7.2 (3.5) | 28.0 (<0.001) |
| Language (max .26) | 25.6 (0.8) | 23.3 (4.2) | 21 (7.2) | 5.4 (0.01) |
| Visuospatial (max .16) | 15.7 (0.6) | 12.8 (3.4) | 12.1 (4.6) | 7.5 (0.001) |
| MMSE (max. 30) | 29.4 (1.2) | 26.9 (2.6) | 25.3 (4.9) | 6.7 (0.002) |
| INECO (max. 30) | 25.7 (2.1) | 17.2 (5.4) | 15.4 (6.5) | 17.9 (<0.0001) |
| PSPRS (max. 100) | - | 32.7 (8.2) | 28.9 (10.0) | 3.4 (0.07) |
| CBFS (max. 120) | - | 32.7 (15.9) | 26.2 (16.2) | 0.2 (0.7) |
| Injected activity (MBq) | ||||
| [11C]UCB-J | 370.7 (114.3) | 322.2 (86.0) | 320.4 (113.8) | ns |
| [18F]AV-1451 | 182.3 (10.8) | 182.1 (11.4) | 186.1 (11.1) | ns |
| [11C]UCB-J and [18F]AV-1451 | 157.2 (125.6) | 155.9 (129.2) | 45.5 (65.7) | 4.6 (0.02) |
| PET scan interval (in days) |